PKD is mainly caused by mutations in the PKD1 and PKD2 genes, affecting polycystin proteins. Disrupted signaling pathways, like cAMP and vasopressin, are major drivers of cyst growth. Tolvaptan is ...

A specially engineered antibody that can infiltrate kidney cysts has shown the ability to block key growth signals driving ...

Polycystic kidney disease (PKD) is a debilitating hereditary condition in which fluid-filled sacs form and proliferate in the ...

In this free webinar, gain insight into the main challenges in patient recruitment for autosomal dominant polycystic kidney disease (ADPKD) clinical trials. Attendees will learn about the clinical ...

Polycystic kidney disease (PKD) is a genetic disorder marked by the growth of many fluid-filled sacs (cysts) in your kidneys. These cysts can grow to replace normal kidney tissue over time, leading to ...

The latest update is out from PYC Therapeutics Limited ( (AU:PYC) ).

Please provide your email address to receive an email when new articles are posted on . Tolvaptan treatment correlated with a slowed annual rate of GFR decline in this population. Tolvaptan may ...

A three-month clinical study on dietary interventions to help treat polycystic kidney disease (PKD) indicates that not only is dietary intervention feasible, it also appears to have resulted in ...

Blocking the inhibition of PKD1 and PKD2 gene expression by deleting a binding site for microRNAs hindered the formation and growth of kidney cysts in autosomal dominant polycystic kidney disease ...

Moreover, the group found that blocking miR-17 binding to PKD1 mRNA with an anti-miR-17 drug after cyst formation also decreased cyst growth, indicating that this interaction could be a promising ...

A new frontier in treating polycystic kidney disease (PKD) has emerged from the labs at the University of California, Santa Barbara. Led by biologist Thomas Weimbs, the team has engineered specialized ...